Sjogren’s Syndrome – Unmet Need – Detailed, Expanded Analysis (US & EU) Primary Sjogren’s Syndrome
No disease-modifying therapies are approved to treat primary Sjögren’s syndrome (pSS), a progressive, autoimmune disease characterized by sicca symptoms, which are caused by chronic inflammation and lymphocytic infiltration of the exocrine glands, as well as potentially severe systemic disease manifestations. Fatigue and arthralgia (joint pain) are among the most common systemic manifestations of pSS, but liver or kidney inflammation, lung involvement, peripheral sensory neuropathy, and vasculitis can also occur. Although immune-targeting agents are used off-label as needed to manage the symptoms of pSS, more-effective options are greatly needed.
QUESTIONS ANSWERED
- What are the key efficacy metrics that surveyed rheumatologists prioritize for pSS? How do respondents rate the performance of off-label therapies on these attributes as well as on safety/tolerability, delivery, and nonclinical factors?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- What are the most compelling unmet needs in the treatment of pSS that would drive positive differentiation in this arena? How well poised are pipeline agents (e.g., Novartis’s iscalimab [CFZ533]) to capitalize on them?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new pSS drug?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in April 2019.
Key companies: Amgen, AstraZeneca, Bristol-Myers Squibb, Galapagos, Gilead, Novartis.
Key drugs: hydroxychloroquine, rituximab, methotrexate, leflunomide, iscalimab, Orencia.
Table of contents
- Sjogren's Syndrome - Unmet Need - Detailed, Expanded Analysis (US & EU) Primary Sjogren's Syndrome
- Primary Sju00f6gren's Syndrome Target Product Profile Simulator
- Introduction
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Rheumatologists' Prescribing Decisions in Primary Sju00f6gren's Syndrome
- Importance of Efficacy Attributes to Prescribing Decisions in Primary Sju00f6gren's Syndrome: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Primary Sju00f6gren's Syndrome: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Primary Sju00f6gren's Syndrome: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Primary Sju00f6gren's Syndrome: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Primary Sju00f6gren's Syndrome: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Primary Sju00f6gren's Syndrome: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Primary Sju00f6gren's Syndrome: United States
- Importance of Nonclinical Factors to Prescribing Decisions in Primary Sju00f6gren's Syndrome: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Primary Sju00f6gren's Syndrome: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Primary Sju00f6gren's Syndrome: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Primary Sju00f6gren's Syndrome: United States
- Overall Performance of Key Therapies for Primary Sju00f6gren's Syndrome: Europe
- Mean Overall Performance of Key Therapies for Primary Sju00f6gren's Syndrome: United States and Europe
- Relative Performance of Key Therapies for Primary Sju00f6gren's Syndrome Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Primary Sju00f6gren's Syndrome Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Primary Sju00f6gren's Syndrome Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Primary Sju00f6gren's Syndrome Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Primary Sju00f6gren's Syndrome Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Primary Sju00f6gren's Syndrome Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Primary Sju00f6gren's Syndrome Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Primary Sju00f6gren's Syndrome Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Primary Sju00f6gren's Syndrome
- Surveyed Rheumatologistsu2019 Satisfaction with the Performance of Key Therapies for Primary Sju00f6gren's Syndrome on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Rheumatologistsu2019 Satisfaction with the Performance of Key Therapies for Primary Sju00f6gren's Syndrome on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Primary Sju00f6gren's Syndrome: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Primary Sju00f6gren's Syndrome: Europe
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Primary Sju00f6gren's Syndrome: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Primary Sju00f6gren's Syndrome: Europe
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Primary Sju00f6gren's Syndrome: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Primary Sju00f6gren's Syndrome: Europe
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Primary Sju00f6gren's Syndrome: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Primary Sju00f6gren's Syndrome: Europe
- Key Findings: Unmet Need in Primary Sju00f6gren's Syndrome and Related Indications
- Surveyed Rheumatologists' Ascribed Level of Unmet Need in Primary Sju00f6gren's Syndrome and Related Indications: United States
- Surveyed Rheumatologists' Ascribed Level of Unmet Need in Primary Sju00f6gren's Syndrome and Related Indications: Europe
- Opportunity Analysis
- Target Product Profiles
- Appendix
John Crowley, Ph.D., is the principal director of the Infectious, Niche, & Rare Diseases team at DRG, part of Clarivate. Prior to his current role, he was a director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. Dr. Crowley holds a Ph.D. from the University of Massachusetts Medical School and a bachelor’s degree from Worcester Polytechnic Institute.